Sofia Vergara's ex wants to prevent two frozen embryos they conceived from being destroyed now that they're broken up. What's the law here?» Read More
Pfizer has launched a fight back against critics of its proposed takeover of AstraZeneca, but did not make any fresh promises on jobs or investment.
Pfizer's $106 billion takeover approach for AstraZeneca is facing mounting scrutiny as senior U.S. politicians weigh in.
Abandoning Obamacare's looming rule that most employers must offer workers health coverage would have little effect on the overall uninsured rate.
The debate in individual states about whether to expand Medicaid eligibility is getting renewed attention as advocates argue it makes financial sense
Allergan is set to reject a $46bn offer by rival Valeant Pharmaceutical, a move likely to spur a takeover battle in the US drug-making industry. FT.
Health insurers are reluctant to cover marijuana, in part because of conflicting laws.
Boston Scientific received a subpoena this week from the Department of Health and Human Services seeking information about its defibrillators.
Pfizer's attempt to escape the United States corporate tax rate has set off a flurry of activity within other big companies across the country, the New York Times reports.
The company tapped to salvage Massachusetts' Obamacare exchange predicts it can finish the job by open enrollment next fall.
It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.
Athenahealth CEO Jonathan Bush tells CNBC that investor David Einhorn's disclosure of a short case against his company allows him to get out and educate investors about its value.
May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments.
Most of the people choosing health plans under the Affordable Care Act — about 80 percent — are paying their initial premiums as required for coverage to take effect, The New York Times reported.
U.K. politicians from the right and the left are piling in to give their two cents on Pfizer's $106 billion bid for AstraZeneca.
Massachusetts' crippled Obamacare exchange is the latest to scrap its existing software, but experts said Tuesday, it likely won't be the last.
Despite all the hoopla, Einhorn's Greenlight Capital is hardly the first to bet against the healthcare service and software company.
Emergency rooms are no less crowded since Obamacare started, Trevor Fetter, CEO of hospital operator Tenet Healthcare, tells CNBC.
Pfizer, one of the world's biggest drugs firms, may have had a $106 billion takeover bid for rival AstraZeneca rejected, but analysts expect it to get its way in the end.
Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.
AstraZeneca, the pharmaceutical company fighting off repeated approaches from larger rival Pfizer, has boosted its defense against the raid.
Get the best of CNBC in your inbox